An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...
Among the general data from the CheckMate 649 trial (NCT02872116) of nivolumab plus chemotherapy, he touched on the continuing debate of using combined positive score (CPS) of PD-L1 as a cut-off, as ...
The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer. The FDA has accepted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback